The introduction of biomolecules into cells is a key technology for research in biological sciences. Transfection, which consists
of introducing nucleic acids into eukaryotic cells, has enabled advances in many fields, including cell and molecular biology,
gene function and regulation studies, and drug target identification and validation. This methodology, based on a simple,
yet sophisticated concept, is also the basis for nucleic acid therapeutics, such as gene therapy and DNA vaccination.
Figure 1
|
Transfection is a standard tool that has been widely used in research for many years. While the introduction of DNA into cells
is routine in most laboratories, it is also possible to deliver other biomolecules, such as messenger RNA (mRNA), small interfering
RNA (siRNA), micro RNA, small hairpin RNA (shRNA) and antisense oligonucleotides, with comparable efficiencies— in particular
using synthetic transfection reagents. The delivery mechanism with a common carrier, such as the cationic polymer polyethylenimine
(PEI), consists of several steps that can be broadly divided into uptake, intracytoplasmic delivery and nuclear import (Figure
1). Recent developments have also enabled the delivery of proteins and antibodies to live cells,1 a novel approach for the study of gene products and signaling pathways. Although widespread, transfection methods are constantly
evolving to provide adapted solutions depending on the applications and the delivered biomolecules. The reagents should also
offer high-transfection efficiencies and low toxicity, and have minimal impact on basic cellular functions and metabolism
upon transfection. They should also overcome several hurdles, including cell entry (Figure 2), release from the endosomes
and nuclear transport, when required.
Figure 2
|
With the fast pace of scientific progress, transfection remains a fast moving technology. The growing use of different cell
types, including primary cells, and the use of novel nucleic acids and other biomolecules with therapeutic potential, place
significant demands on existing techniques. In addition, increasing requests by researchers encourage novel developments.
Gene therapy
Figure 3
|
Gene therapy — defined as a method for transferring functional genetic material to cure diseases or to improve the clinical
status of a patient — requires therapeutic DNA to be delivered to the nucleus of the cells of a particular organ using a safe
and efficient delivery system, adding a level of complexity compared to in vitro transfection. To date, viral-based vectors have been used extensively because of their innate ability to deliver DNA to cells
as they naturally infect host cells to replicate. These vectors consist of genetically modified viruses such as replication-incompetent
viruses that contain the gene of interest. The most commonly used ones are retroviruses, adenoviruses, adeno-associated viruses,
vaccinia viruses and pox viruses. The efficiency at which they transduce cells and the potential long-term expression of the
transgene explain, in part, why viral vectors represent approximately 68% of ongoing clinical trials to date (Figure 3).2Despite progress leading to the generation of safer viral vectors, safety considerations, such as pathogenicity, oncogenicity
and immune responses in the host, remain a concern. For example, despite clear successes, serious adverse effects have been
observed in several SCID-X1 gene therapy trials because of overexpression of a proto-oncogene, which has led to the development
of leukemia caused by retroviral vector insertions.3 Other serious adverse effects have been observed with adenoviruses and adeno-associated viruses.3 This has, in part, focused development on physical and nonviral gene delivery systems, which represent 27% of gene therapy
clinical trials (Figure 3).4,5
KIMTECH PURE A5 Sterile Cleanroom Apparel. Designed to make it easier to put on the coveralls without compromising their sterility
Transdermal Delivery of Vaccines and Proteins using a Hand-Applied, Polymeric Microstructured Array. Download poster.
BioAnalytical Quality Standard Initiative - Implementing ICH Q10 for Clinical Trials
DSM pharma dosage forms - Solids, Steriles, and Packaging
See how the XPert Weigh Box provides glove box protection at an affordable price
Shimadzu Nexera UHPLC meets all analysis requirements with no compromise in data integrity
Special offers on new and improved products from Restek
Buying and Selling New, Reconditioned, and Used Equipment for the Process and Packaging Industries - Since 1991
Aseptic liquid filling and capping equipment
See the latest news from Optima Group pharma.